Advancing Antibody-Based Therapies

We are Patient Centric

We are Science-Based

We are Performance Driven

We are at the ASCO Annual Meeting

June 1 – 3, 2019
Location: McCormick Place, Chicago

Goldman Sachs 40th Annual Global Healthcare Conference

The Company participated in a fireside chat on Tuesday, June 11, 2019 at 2:00 p.m. Pacific Time. To access recording of audio webcast, click here

Jefferies 2019 Global Healthcare Conference

The Company participated in a fireside chat on Wednesday, June 5, 2019, at 11:00 a.m. Eastern Time. To access recording of audio webcast, click here.

Immunomedics First Quarter 2019 Earnings Call

The Company hosted a conference call and live audio webcast on May 9, 2019, at 8:00 am Eastern Time. To access recording of this conference call, click here

Cowen and Company 39th Annual Health Care Conference

The Company will participate in a fireside chat on Monday, March 11, 2019 at 2:10 p.m. Eastern Time. To access a live audio webcast, click here.

Immunomedics Transition Period 2018 Earnings Call

The Company hosted a conference call and live audio webcast on Feburary 25, 2019 at 5:00 pm Eastern Time. To access the conference call, click here.

Immunomedics Company Update - January 18, 2019

The Company hosted a conference call and live audio webcast on January 18, 2019 at 8:00 am Eastern Time. To access the conference call, click here.

37th Annual J.P. Morgan Healthcare Conference

On Thursday, January 10, 2019 at 7:30am Pacific Time, Michael Pehl, President and Chief Executive Officer, presented an overview of the Company and its strategic priorities at the 37th Annual J.P. Morgan Healthcare Conference.

More Information

Piper Jaffrey Healthcare 2018

To access the live webcast and the webcast replay of the presentation, click here.

Immunomedics Announces Presentation At Upcoming Healthcare Conferences

Click here to access a live webcast for the Credit Suisse 27th Annual Healthcare Conference

Immunomedics to report first quarter fiscal 2019 results and host conference call and webcast on November 7, 2018

To access the conference call, visit https://edge.media-server.com/m6/p/8qjdm6y5

Immunomedics Expands Clinical Collaboration with AstraZeneca to Include Metastatic Non-Small Lung Cancer

Immunomedics Announces First Quarter Fiscal 2019 Results and Provides Corporate Update

October 31, 2018

Immunomedics to report first quarter fiscal 2019 results and host conference call and webcast on November 7, 2018

September 12, 2018

Immunomedics and Samsung Biologics Announce Strategic Manufacturing Partnership

Baird 2018 Global Healthcare Conference

On Wednesday, September 5, 2018 at 9:05 a.m. Eastern Time, Michael Pehl, President and Chief Executive Officer, will present an overview of the Company at Baird 2018 Global Healthcare Conference.

2018 Wells Fargo Healthcare Conference

On Thursday, September 6, 2018 at 1:20 p.m. Eastern Time, Michael Pehl, President and Chief Executive Officer, will present an overview of the Company at 2018 Wells Fargo Healthcare Conference.

Morgan Stanley 16th Annual Global Healthcare Conference

On Wednesday, September 12, 2018 at 4:15 p.m. Eastern Time, Michael Pehl, President and Chief Executive Officer, will participate in a fireside chat at Morgan Stanley 16th Annual Global Healthcare Conference.

Our Drive to Improve Targeted Therapies of Diseases

We have assembled significant expertise in antibody engineering, particularly proprietary CDR-grafting methods, antibody production and formulation, immunochemistry, molecular biology, antibody conjugation, peptide chemistry, synthetic organic chemistry, and protein engineering.

Our Science

Pipeline

We believe that each of our antibodies has therapeutic potential either when administered as a naked antibody or when conjugated with therapeutic radioisotopes (radiolabeled), chemotherapeutics, cytokines or other toxins to create unique and potentially more effective treatment options.

Learn More

Explore how we turn our research into reality.

Immunomedics is sponsoring an international Phase 3 clinical trial in patients with relapsed triple-negative breast cancer who have previously received two or more therapies for their metastatic disease.

Clinical Trials